| Identification | Back Directory | [Name]
1-Piperazineacetamide, N-[5-[(Z)-[6-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-4-methyl- | [CAS]
2760584-90-3 | [Synonyms]
1-Piperazineacetamide, N-[5-[(Z)-[6-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-4-methyl- | [Molecular Formula]
C30H38N8O4 | [MOL File]
2760584-90-3.mol | [Molecular Weight]
574.67 |
| Chemical Properties | Back Directory | [Boiling point ]
723.0±60.0 °C(Predicted) | [density ]
1.334±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
12.62±0.70(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Biological Activity]
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity[1]. | [storage]
Store at -20°C | [References]
[1]. Lv Q, et al. Discovery of (Z)-1-(3-((1H-Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea Derivatives as Novel and Orally Highly Effective CSF-1R Inhibitors for Potential Colorectal Cancer Immunotherapy. J Med Chem. 2021;64(23):17184-17208. |
|
|